Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial
Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness, tolerability, and safety of combining montelukast therapy...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1153653/full |
| _version_ | 1797849193460531200 |
|---|---|
| author | Eman El-Khateeb Eman El-Khateeb Eman I. El-Berri Esraa M. Mosalam Mohamed Z. Nooh Shimaa Abdelsattar Amira M. Alghamdi Sarah Alrubia Mahmoud S. Abdallah |
| author_facet | Eman El-Khateeb Eman El-Khateeb Eman I. El-Berri Esraa M. Mosalam Mohamed Z. Nooh Shimaa Abdelsattar Amira M. Alghamdi Sarah Alrubia Mahmoud S. Abdallah |
| author_sort | Eman El-Khateeb |
| collection | DOAJ |
| description | Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness, tolerability, and safety of combining montelukast therapy with metformin in obese diabetic patients.Methods: One hundred obese diabetic adult patients were recruited and randomized into two equal groups. Group 1 received placebo plus metformin 2 g/d, and Group 2 received 2 g/d metformin plus 10 mg/d montelukast. Demographic, anthropometric measurements (e.g., body weight, body mass index [BMI], and visceral adiposity index), lipid profile, diabetes control measures (fasting blood glucose, glycated hemoglobin [HbA1c], and homeostatic model assessment for insulin resistance [HOMA-IR]), adiponectin, and inflammatory markers (e.g., TNF-α, IL-6, and leukotriene B4) were assessed and reported for each group at baseline and after 12 weeks of treatment.Results: Both interventions significantly reduced all the measured parameters, except for adiponectin and HDL-C, levels of which increased compared to baseline data (p < 0.001). The montelukast group significantly improved in all parameters compared to the placebo group (ANCOVA test p < 0.001). The percentage changes in BMI, HbA1c, HOMA-IR, and inflammatory markers were 5%, 9%, 41%, and 5%–30%, respectively, in the placebo group compared to 8%, 16%, 58%, and 50%–70%, respectively, in the montelukast group.Conclusion: Montelukast adjuvant therapy was superior to metformin-only therapy in diabetes control and weight loss, most likely due to its increased insulin sensitivity and anti-inflammatory properties. The combination was tolerable and safe throughout the study duration.Clinical Trial Registration: [Clinicaltrial.gov], identifier [NCT04075110]. |
| first_indexed | 2024-04-09T18:40:58Z |
| format | Article |
| id | doaj.art-ab8fabb54ec5483a9b9a4781012c558d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T18:40:58Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ab8fabb54ec5483a9b9a4781012c558d2023-04-11T05:58:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.11536531153653Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trialEman El-Khateeb0Eman El-Khateeb1Eman I. El-Berri2Esraa M. Mosalam3Mohamed Z. Nooh4Shimaa Abdelsattar5Amira M. Alghamdi6Sarah Alrubia7Mahmoud S. Abdallah8Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, EgyptCertara UK Limited (Simcyp Division), Sheffield, United KingdomDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, EgyptDepartment of Biochemistry, Faculty of Pharmacy, Menoufia University, Shebin ElKoum, EgyptDepartment of Internal Medicine, Faculty of Medicine, Menoufia University, Shebin ElKoum, EgyptDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebin ElKoum, EgyptDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi ArabiaPharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City, Sadat City, Menoufia, EgyptBackground: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness, tolerability, and safety of combining montelukast therapy with metformin in obese diabetic patients.Methods: One hundred obese diabetic adult patients were recruited and randomized into two equal groups. Group 1 received placebo plus metformin 2 g/d, and Group 2 received 2 g/d metformin plus 10 mg/d montelukast. Demographic, anthropometric measurements (e.g., body weight, body mass index [BMI], and visceral adiposity index), lipid profile, diabetes control measures (fasting blood glucose, glycated hemoglobin [HbA1c], and homeostatic model assessment for insulin resistance [HOMA-IR]), adiponectin, and inflammatory markers (e.g., TNF-α, IL-6, and leukotriene B4) were assessed and reported for each group at baseline and after 12 weeks of treatment.Results: Both interventions significantly reduced all the measured parameters, except for adiponectin and HDL-C, levels of which increased compared to baseline data (p < 0.001). The montelukast group significantly improved in all parameters compared to the placebo group (ANCOVA test p < 0.001). The percentage changes in BMI, HbA1c, HOMA-IR, and inflammatory markers were 5%, 9%, 41%, and 5%–30%, respectively, in the placebo group compared to 8%, 16%, 58%, and 50%–70%, respectively, in the montelukast group.Conclusion: Montelukast adjuvant therapy was superior to metformin-only therapy in diabetes control and weight loss, most likely due to its increased insulin sensitivity and anti-inflammatory properties. The combination was tolerable and safe throughout the study duration.Clinical Trial Registration: [Clinicaltrial.gov], identifier [NCT04075110].https://www.frontiersin.org/articles/10.3389/fphar.2023.1153653/fullmontelukastT2DMobesityleukotriene receptor antagonistmetformindiabetes |
| spellingShingle | Eman El-Khateeb Eman El-Khateeb Eman I. El-Berri Esraa M. Mosalam Mohamed Z. Nooh Shimaa Abdelsattar Amira M. Alghamdi Sarah Alrubia Mahmoud S. Abdallah Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial Frontiers in Pharmacology montelukast T2DM obesity leukotriene receptor antagonist metformin diabetes |
| title | Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial |
| title_full | Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial |
| title_fullStr | Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial |
| title_full_unstemmed | Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial |
| title_short | Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial |
| title_sort | evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus a double blind randomized placebo controlled trial |
| topic | montelukast T2DM obesity leukotriene receptor antagonist metformin diabetes |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1153653/full |
| work_keys_str_mv | AT emanelkhateeb evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT emanelkhateeb evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT emanielberri evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT esraammosalam evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT mohamedznooh evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT shimaaabdelsattar evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT amiramalghamdi evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT sarahalrubia evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial AT mahmoudsabdallah evaluatingthesafetyandefficacyoftheleukotrienereceptorantagonistmontelukastasadjuvanttherapyinobesepatientswithtype2diabetesmellitusadoubleblindrandomizedplacebocontrolledtrial |